Author

Emiliano Giangreco

VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE
VEDOLIZUMAB MAY BE AN EFFECTIVE OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE

Emiliano Giangreco  et al.

EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN BIOLOGIC-NAïVE PATIENTS: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)
EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN BIOLOGIC-NAïVE PATIENTS: REAL-WORLD DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASES (SN-IBD)

Emiliano Giangreco  et al.

SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501
SPOSAB ABP 501 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH ADALIMUMAB BIOSIMILAR ABP 501

Emiliano Giangreco  et al.

SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)
SEVERE ACTIVITY OF INFLAMMATORY BOWEL DISEASE IS A RISK FACTOR FOR SEVERE COVID-19: DATA FROM THE SICILIAN NETWORK FOR INFLAMMATORY BOWEL DISEASE (SN-IBD)

Emiliano Giangreco  et al.

SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS
SPOSIB SB2 - A SICILIAN PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB BIOSIMILAR SB2: FINAL RESULTS

Emiliano Giangreco  et al.

Item 1 - 5 / 5
1